Cargando…

Next‐generation sequencing clarified why first‐line treatment with osimertinib was ineffective in an autopsied case of EGFR‐mutated lung squamous cell carcinoma

Epidermal growth factor receptor (EGFR)‐mutated squamous cell carcinoma (SCC) is less common than adenocarcinoma. The third‐generation EGFR‐tyrosine kinase inhibitor, osimertinib, is effective in EGFR‐mutated lung adenocarcinoma, but its efficacy in EGFR‐mutated lung SCC is unclear. The patient was...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishimura, Tadashi, Fujiwara, Takumi, Fujimoto, Hajime, Tarumi, Hirotoshi, Tsuji, Chikashi, Iwanaka, Soichi, Sakakura, Yasumasa, Naito, Masahiro, Okugawa, Yoshinaga, Yasuma, Taro, Gabazza, Esteban Cesar, Oomoto, Yasuhiro, Kobayashi, Tetsu, Ibata, Hidenori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981312/
https://www.ncbi.nlm.nih.gov/pubmed/36710365
http://dx.doi.org/10.1111/1759-7714.14807
_version_ 1784900074617176064
author Nishimura, Tadashi
Fujiwara, Takumi
Fujimoto, Hajime
Tarumi, Hirotoshi
Tsuji, Chikashi
Iwanaka, Soichi
Sakakura, Yasumasa
Naito, Masahiro
Okugawa, Yoshinaga
Yasuma, Taro
Gabazza, Esteban Cesar
Oomoto, Yasuhiro
Kobayashi, Tetsu
Ibata, Hidenori
author_facet Nishimura, Tadashi
Fujiwara, Takumi
Fujimoto, Hajime
Tarumi, Hirotoshi
Tsuji, Chikashi
Iwanaka, Soichi
Sakakura, Yasumasa
Naito, Masahiro
Okugawa, Yoshinaga
Yasuma, Taro
Gabazza, Esteban Cesar
Oomoto, Yasuhiro
Kobayashi, Tetsu
Ibata, Hidenori
author_sort Nishimura, Tadashi
collection PubMed
description Epidermal growth factor receptor (EGFR)‐mutated squamous cell carcinoma (SCC) is less common than adenocarcinoma. The third‐generation EGFR‐tyrosine kinase inhibitor, osimertinib, is effective in EGFR‐mutated lung adenocarcinoma, but its efficacy in EGFR‐mutated lung SCC is unclear. The patient was an 83‐year‐old male. He was diagnosed with SCC of the lung, and molecular analysis revealed that the tumor was positive for EGFR exon19 deletion. He was treated with osimertinib 80 mg/day. No adverse events were observed, but after 18 days of therapy, he complained of dyspnea, and a computed tomography scan showed enlarged lung cancer. The case was categorized as a progressive disease. The patient died 3 weeks later. The autopsy findings confirmed the diagnosis of lung SCC, with morphology and immunohistochemical staining identical to the tumor obtained by bronchoscopy. Next‐generation sequencing showed the presence of TP53 R158L, CDK6, and KRAS amplifications. The current case report shows that next‐generation sequencing can explain why osimertinib is ineffective in EGFR‐mutated SCC.
format Online
Article
Text
id pubmed-9981312
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-99813122023-03-03 Next‐generation sequencing clarified why first‐line treatment with osimertinib was ineffective in an autopsied case of EGFR‐mutated lung squamous cell carcinoma Nishimura, Tadashi Fujiwara, Takumi Fujimoto, Hajime Tarumi, Hirotoshi Tsuji, Chikashi Iwanaka, Soichi Sakakura, Yasumasa Naito, Masahiro Okugawa, Yoshinaga Yasuma, Taro Gabazza, Esteban Cesar Oomoto, Yasuhiro Kobayashi, Tetsu Ibata, Hidenori Thorac Cancer Case Report Epidermal growth factor receptor (EGFR)‐mutated squamous cell carcinoma (SCC) is less common than adenocarcinoma. The third‐generation EGFR‐tyrosine kinase inhibitor, osimertinib, is effective in EGFR‐mutated lung adenocarcinoma, but its efficacy in EGFR‐mutated lung SCC is unclear. The patient was an 83‐year‐old male. He was diagnosed with SCC of the lung, and molecular analysis revealed that the tumor was positive for EGFR exon19 deletion. He was treated with osimertinib 80 mg/day. No adverse events were observed, but after 18 days of therapy, he complained of dyspnea, and a computed tomography scan showed enlarged lung cancer. The case was categorized as a progressive disease. The patient died 3 weeks later. The autopsy findings confirmed the diagnosis of lung SCC, with morphology and immunohistochemical staining identical to the tumor obtained by bronchoscopy. Next‐generation sequencing showed the presence of TP53 R158L, CDK6, and KRAS amplifications. The current case report shows that next‐generation sequencing can explain why osimertinib is ineffective in EGFR‐mutated SCC. John Wiley & Sons Australia, Ltd 2023-01-29 /pmc/articles/PMC9981312/ /pubmed/36710365 http://dx.doi.org/10.1111/1759-7714.14807 Text en © 2023 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Report
Nishimura, Tadashi
Fujiwara, Takumi
Fujimoto, Hajime
Tarumi, Hirotoshi
Tsuji, Chikashi
Iwanaka, Soichi
Sakakura, Yasumasa
Naito, Masahiro
Okugawa, Yoshinaga
Yasuma, Taro
Gabazza, Esteban Cesar
Oomoto, Yasuhiro
Kobayashi, Tetsu
Ibata, Hidenori
Next‐generation sequencing clarified why first‐line treatment with osimertinib was ineffective in an autopsied case of EGFR‐mutated lung squamous cell carcinoma
title Next‐generation sequencing clarified why first‐line treatment with osimertinib was ineffective in an autopsied case of EGFR‐mutated lung squamous cell carcinoma
title_full Next‐generation sequencing clarified why first‐line treatment with osimertinib was ineffective in an autopsied case of EGFR‐mutated lung squamous cell carcinoma
title_fullStr Next‐generation sequencing clarified why first‐line treatment with osimertinib was ineffective in an autopsied case of EGFR‐mutated lung squamous cell carcinoma
title_full_unstemmed Next‐generation sequencing clarified why first‐line treatment with osimertinib was ineffective in an autopsied case of EGFR‐mutated lung squamous cell carcinoma
title_short Next‐generation sequencing clarified why first‐line treatment with osimertinib was ineffective in an autopsied case of EGFR‐mutated lung squamous cell carcinoma
title_sort next‐generation sequencing clarified why first‐line treatment with osimertinib was ineffective in an autopsied case of egfr‐mutated lung squamous cell carcinoma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981312/
https://www.ncbi.nlm.nih.gov/pubmed/36710365
http://dx.doi.org/10.1111/1759-7714.14807
work_keys_str_mv AT nishimuratadashi nextgenerationsequencingclarifiedwhyfirstlinetreatmentwithosimertinibwasineffectiveinanautopsiedcaseofegfrmutatedlungsquamouscellcarcinoma
AT fujiwaratakumi nextgenerationsequencingclarifiedwhyfirstlinetreatmentwithosimertinibwasineffectiveinanautopsiedcaseofegfrmutatedlungsquamouscellcarcinoma
AT fujimotohajime nextgenerationsequencingclarifiedwhyfirstlinetreatmentwithosimertinibwasineffectiveinanautopsiedcaseofegfrmutatedlungsquamouscellcarcinoma
AT tarumihirotoshi nextgenerationsequencingclarifiedwhyfirstlinetreatmentwithosimertinibwasineffectiveinanautopsiedcaseofegfrmutatedlungsquamouscellcarcinoma
AT tsujichikashi nextgenerationsequencingclarifiedwhyfirstlinetreatmentwithosimertinibwasineffectiveinanautopsiedcaseofegfrmutatedlungsquamouscellcarcinoma
AT iwanakasoichi nextgenerationsequencingclarifiedwhyfirstlinetreatmentwithosimertinibwasineffectiveinanautopsiedcaseofegfrmutatedlungsquamouscellcarcinoma
AT sakakurayasumasa nextgenerationsequencingclarifiedwhyfirstlinetreatmentwithosimertinibwasineffectiveinanautopsiedcaseofegfrmutatedlungsquamouscellcarcinoma
AT naitomasahiro nextgenerationsequencingclarifiedwhyfirstlinetreatmentwithosimertinibwasineffectiveinanautopsiedcaseofegfrmutatedlungsquamouscellcarcinoma
AT okugawayoshinaga nextgenerationsequencingclarifiedwhyfirstlinetreatmentwithosimertinibwasineffectiveinanautopsiedcaseofegfrmutatedlungsquamouscellcarcinoma
AT yasumataro nextgenerationsequencingclarifiedwhyfirstlinetreatmentwithosimertinibwasineffectiveinanautopsiedcaseofegfrmutatedlungsquamouscellcarcinoma
AT gabazzaestebancesar nextgenerationsequencingclarifiedwhyfirstlinetreatmentwithosimertinibwasineffectiveinanautopsiedcaseofegfrmutatedlungsquamouscellcarcinoma
AT oomotoyasuhiro nextgenerationsequencingclarifiedwhyfirstlinetreatmentwithosimertinibwasineffectiveinanautopsiedcaseofegfrmutatedlungsquamouscellcarcinoma
AT kobayashitetsu nextgenerationsequencingclarifiedwhyfirstlinetreatmentwithosimertinibwasineffectiveinanautopsiedcaseofegfrmutatedlungsquamouscellcarcinoma
AT ibatahidenori nextgenerationsequencingclarifiedwhyfirstlinetreatmentwithosimertinibwasineffectiveinanautopsiedcaseofegfrmutatedlungsquamouscellcarcinoma